Continuous Glucose Monitoring and Time in Range: Association with Adverse Outcomes among People with Type 2 or Gestational Diabetes Mellitus

被引:12
作者
Bitar, Ghamar [1 ,4 ]
Cornthwaite, Joycelyn A. [1 ]
Sadek, Sandra [1 ]
Ghorayeb, Tala [1 ]
Daye, Nahla [1 ]
Nazeer, Sarah [1 ]
Ghafir, Danna [1 ]
Cornthwaite, John [2 ]
Chauhan, Suneet P. [1 ]
Sibai, Baha M. [1 ]
Bartal, Michal Fishel [1 ,3 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Obstet & Gynecol, Div Maternal Fetal Med, Houston, TX USA
[2] Rice Univ, Dept Earth Environm & Planetary Sci, Houston, TX USA
[3] Tel Aviv Univ, Sheba Med Ctr Tel Hashomer, Sackler Sch Med, Dept Obstet & Gynecol, Tel Aviv, Israel
[4] Univ Texas Hlth Sci Ctr Houston, Dept Obstet & Gynecol & Reprod Sci, Houston, TX 77030 USA
关键词
diabetes; pregnancy; continuous glucose monitoring; time in range; neonatal outcomes; maternal outcomes; PREGNANT-WOMEN; GLYCEMIC CONTROL; RECOMMENDATIONS; HYPOGLYCEMIA; MANAGEMENT;
D O I
10.1055/s-0043-1764208
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective Continuous glucose monitoring (CGM) has become available for women with type 2 diabetes mellitus (T2DM) or gestational diabetes mellitus (GDM) during pregnancy. The recommended time in range (TIR, blood glucose 70-140 mg/dL) and its correlation with adverse pregnancy outcomes in this group is unknown. Our aim was to compare maternal and neonatal outcomes in pregnant people with T2DM or GDM with average CGM TIR values > 70 versus < 70%.Study Design We conducted a retrospective cohort study of all individuals using CGM during pregnancy from January 2017 to June 2022. Individuals with type 1 diabetes mellitus, or those missing CGM or delivery data were excluded. Primary composite neonatal outcome included any of the following: large for gestational age, NICU admission, need for intravenous glucose, respiratory support, or neonatal death. Secondary outcomes included other maternal and neonatal outcomes. Regression models were used to estimate adjusted odds ratio (aOR) and 95% confidence interval (CI).Results During the study period, 141 individuals with diabetes utilized CGM during pregnancy, with 65 (46%) meeting inclusion criteria. Of the study population, 28 (43%) had TIR < 70% and 37 (57%) had TIR > 70%. Compared with those with TIR > 70%, the primary composite outcome occurred more frequently in neonates of individuals TIR < 70% (71.4 vs. 37.8%, aOR: 4.8, 95% CI: 1.6, 15.7). Furthermore, individuals with TIR < 70% were more likely to have hypertensive disorders (42.9 vs. 16.2%, OR: 3.9, 95% CI: 1.3, 13.0), preterm delivery (54 vs. 27%, OR: 3.1, 95% CI: 1.1, 9.1), and cesarean delivery (96.4 vs. 51.4%, OR: 4.6, 95% CI: 2.2, 15.1) compared with those with TIR > 70%.Conclusion Among people with T2DM or GDM who utilized CGM during pregnancy, 4 out 10 individuals had TIR < 70% and, compared with those with TIR > 70%, they had a higher likelihood of adverse neonatal and maternal outcomes.
引用
收藏
页码:e1370 / e1377
页数:8
相关论文
共 50 条
  • [31] Continuous glucose monitoring in type 2 diabetes
    Harman-Boehm, Ilana
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 : S118 - S121
  • [32] Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study
    Wang, Yaxin
    Lu, Jingyi
    Shen, Yun
    Ni, Jiaying
    Zhang, Lei
    Lu, Wei
    Zhu, Wei
    Bao, Yuqian
    Zhou, Jian
    ENDOCRINE, 2022, 76 (03) : 593 - 600
  • [33] Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting
    Mcqueen, Robert Brett
    Perez-Nieves, Magaly
    Alonso, G. Todd
    Fan, Ludi
    Hankosky, Emily R.
    Shah, Viral N.
    Yan, Yuer
    Ellis, Samuel L.
    Juneja, Rattan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 212
  • [34] Utility of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes
    Toschi, Elena
    Wolpert, Howard
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2016, 45 (04) : 895 - +
  • [35] Continuous Glucose Monitoring Time-in-Range and HbA1c Targets in Pregnant Women with Type 1 Diabetes
    Tundidor, Diana
    Meek, Claire L.
    Yamamoto, Jennifer
    Martinez-Bru, Cecilia
    Gich, Ignasi
    Feig, Denice S.
    Murphy, Helen R.
    Corcoy, Rosa
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (10) : 710 - 714
  • [36] A Pilot Trial of Continuous Glucose Monitoring Upon Emergency Department Discharge Among People With Diabetes Mellitus
    O'Connor, Mark J.
    Ding, Xinyi
    Hernandez, Camila
    Hubacz, Lisa
    Church, Richard J.
    O'Connor, Laurel
    ENDOCRINE PRACTICE, 2024, 30 (02) : 122 - 127
  • [37] Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications
    Li, Zoey
    Beck, Roy
    Durnwald, Celeste
    Carlson, Anders
    Norton, Elizabeth
    Bergenstal, Richard
    Johnson, Mary
    Dunnigan, Sean
    Banfield, Matthew
    Krumwiede, Katie
    Sibayan, Judy
    Calhoun, Peter
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (11) : 787 - 796
  • [38] Continuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study
    Di Filippo, Daria
    Ahmadzai, Marrwah
    Chang, Melissa Han Yiin
    Horgan, Ksana
    Ong, Ru Min
    Darling, Justine
    Akhtar, Mahmood
    Henry, Amanda
    Welsh, Alec
    JOURNAL OF DIABETES RESEARCH, 2022, 2022
  • [39] Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD
    Presswala, Lubaina
    Hong, Susana
    Harris, Yael
    Romao, Isabela
    Zhang, Meng
    Jhaveri, Kenar D.
    Sakhiya, Vipul
    Fishbane, Steven
    KIDNEY MEDICINE, 2019, 1 (05) : 281 - 287
  • [40] Cutaneous adverse events in a randomized controlled trial of flash glucose monitoring among youth with type 1 diabetes mellitus
    Marsters, Brooke L.
    Boucher, Sara E.
    Galland, Barbara C.
    Wiltshire, Esko J.
    de Bock, Martin I.
    Tomlinson, Paul A.
    Rayns, Jenny
    MacKenzie, Karen E.
    Chan, Huan
    Wheeler, Benjamin J.
    PEDIATRIC DIABETES, 2020, 21 (08) : 1516 - 1524